Sinotau Pharmaceutical

Sinotau Pharmaceutical, based in Beijing, China, is a radiopharmaceutical company. Sinotau specialises in the research and development, production, clinical application and academic promotion of radiopharmaceutical drugs, with therapeutic focus areas in oncology, neurology and cardiology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Octreotide LAR in neuroendocrine tumours. The largest, NCT05459844 (A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs), plans to enrol 196 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.